We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NEW DATA LINKS ADHD DRUGS TO EMERGENCY ROOM VISITS

NEW DATA LINKS ADHD DRUGS TO EMERGENCY ROOM VISITS

May 30, 2006

A study released by the Centers for Disease Control (CDC) finds that patients taking stimulants for attention deficit hyperactivity disorder (ADHD) are making frequent trips to the emergency room amid a growing debate over the drugs' labeling.

The study, published in the New England Journal of Medicine (NEJM), studied emergency room data from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance (NEISS-CADES) project and estimated that 3,075 people visited emergency rooms in 2004 for adverse events caused by ADHD drugs.

"We found that visits to an emergency department for adverse drug events due to stimulant medications are not uncommon," the study concludes, adding that "the NEISS-CADES project probably underestimates the number of adverse drug events that are rare, previously unreported or difficult to diagnose" in an emergency room.

This study comes at a time when the content of ADHD drug labels is being hotly debated. While the FDA already plans to require the labels to carry additional warnings on use in children with cardiac conditions and other factors, some are calling for a black box warning for the drugs.

Steven Nissen, interim chairman of the Cleveland Clinic's Department of Cardiovascular Medicine and a consultant to the Drug Safety and Risk Management Advisory Committee that reviewed ADHD drugs, urges that approach, writing in the same edition of NEJM that it is a "fundamental fact that increasing heart rate and blood pressure by the administration of powerful cardiac stimulants is inherently risky." Several closely related compounds, ephedra and phenylpropanolamine, are so dangerous the FDA has banned them altogether, he wrote.

KEYWORDS Daily International Pharma Alert

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

  • Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing